Evaluation of autoantibodies as predictors of treatment response and immune‐related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan‐cancer study-Reference-Cited by-同舟云学术

Evaluation of autoantibodies as predictors of treatment response and immune‐related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan‐cancer study

Published:2022-03-16 Issue:16 Volume:11 Page:3074-3083
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Barth Dominik A.¹^ORCID,Stanzer Stefanie¹,Spiegelberg Jasmin¹,Bauernhofer Thomas¹,Absenger Gudrun¹,Posch Florian¹²,Lipp Rainer¹,Halm Michael¹,Szkandera Joanna¹,Balic Marija¹,Gerger Armin¹^ORCID,Smolle Maria A.³,Hutterer Georg C.⁴,Klec Christiane¹,Jost Philipp J.¹,Kargl Julia⁵⁶,Stradner Martin⁷,Pichler Martin¹⁸^ORCID

Affiliation:

1. Division of Oncology Department of Internal Medicine, Medical University of Graz Graz Austria

2. Division of Haematology Department of Internal Medicine, Medical University of Graz Graz Austria

3. Department of Orthopaedics and Trauma Medical University of Graz Graz Austria

4. Department of Urology Medical University of Graz Graz Austria

5. Otto Loewi Research Center Division of Pharmacology, Medical University of Graz Graz Austria

6. BioTechMed‐Graz Graz Austria

7. Division of Rheumatology Department of Internal Medicine, Medical University of Graz Graz Austria

8. Department of Experimental Therapeutics The University of Texas MD Anderson Cancer Center Houston Texas USA

Funder

Austrian Science Fund

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4675

Reference30 articles.

1. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

2. Mechanisms of resistance to immune checkpoint inhibitors

3. Nivolumab plus Ipilimumab in Advanced Melanoma

4. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

5. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Distinct autoantibody profiles across checkpoint inhibitor types and toxicities;OncoImmunology;2024-05-09

2. Immune Checkpoint Therapy–Induced Lupus Nephritis;Kidney International Reports;2024-05

3. The Current and Future of Biomarkers of Immune Related Adverse Events;Rheumatic Disease Clinics of North America;2024-05

4. Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors;Cancers;2024-03-20

5. Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma;Immunotherapy;2024-01-24